Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q1 FY22 Earnings Presentation
20 slides from Camlin Fine Sciences's earnings presentation, Aug 13, 2021
Slide 1: Intimation to stock exchanges under SEBI Regulation 30
13th August, 2021 To, To, BSE Limited, The Manager, 25, P. J. Towers, Listing Department, Dalal Street, National Stock Exchange of India Ltd., Mumbai – 400 001 Exchange Plaza, Bandra Kurla Complex, Ref: Company Scrip Code: 532834 Bandra (East), Mumbai‐ 400051 Ref: Symbol: CAMLINFINE || Series: EQ Su
Slide 2: Earnings Presentation Q1-FY22
EARNINGS PRESENTATION Q1-FY22
Slide 3: Snapshot
Snapshot One of the few end-to-end Strong management team with Global experience with local 5 Manufacturing Facilities integrated specialty chemicals experienced industry professionals presence 2 R&D Centres company 5 Application Labs Diversified product basket of over Established customer base of o
Slide 4: About the Company
About the Company • Camlin Fine Sciences Limited (CFS) was formed in 2006 after de-merging the fine Total Operational Revenue (INR Mn) chemical business from Camlin Ltd and got listed on the BSE and NSE in 2007 and 2011, respectively. 11,871 10,491 • It is a vertically integrated company, engaged in
Slide 5: Q1-FY22 Financial Overview
} QI-FY22 FINANCIAL OVERVIEW
Slide 6: Q1-FY22 Financial Highlights
Q1-FY22 Financial Highlights Q1-FY22 Financial Highlights (Consolidated): Q1-FY22 Financial Highlights (Standalone): INR 3,308 Mn INR 456 Mn INR 456 Mn INR 238 Mn INR 1,457 Mn INR 192 Mn INR 192 Mn INR 47 Mn Total Revenue EBITDA Adjusted EBITDA PAT Total Revenue EBITDA Adjusted EBITDA PAT 13.78% 13.
Slide 7: Q1-FY22 Operational Highlights (Consolidated)
Q1-FY22 Operational Highlights (Consolidated) • Resilient performance despite continued challenges on account of Covid pandemic. • Continued pressure on margins due to increasing global raw material prices, logistic costs and supply chain issues. Suitable steps undertaken through increase in product
Slide 8: Q1-FY22 Standalone Income Statement (Ind-AS)
Q1-FY22 Standalone Income Statement (Ind-AS) Income Statement (Mn) Q1-FY22 Q4-FY21 Q-o-Q Q1-FY21 Y-o-Y Operational Revenue 1,457 1,685 (13.5)% 1,212 20.2% Total Expenses 1,265 1,478 (14.4)% 1,049 20.6% Operational EBITDA 192 207 (7.2)% 163 17.8% Operational EBITDA Margins (%) 13.18% 12.28% 90 Bps 13
Slide 9: Q1-FY22 Consolidated Income Statement (Ind-AS)
Q1-FY22 Consolidated Income Statement (Ind-AS) Income Statement (INR Mn) Q1-FY22 Q4-FY21 Q-o-Q Q1-FY21 Y-o-Y Operational Revenue 3,308 3,266 1.3% 3,057 8.2% Total Expenses 2,852 2,762 3.3% 2,547 12.0% Operational EBITDA 456 504 (9.5)% 510 (10.6)% Operational EBITDA Margins (%) 13.78% 15.43% (165) Bp
Slide 10: Country Overview
COUNTRY OVERVIEW
Slide 11: Country Wise Quarterly Performance
Country Wise Quarterly Performance CFS India CFS Mexico CFS Europe Quarterly Operational 1,685 1,119 1,060 Revenue (INR Mn) 723 751 695 996 1,457 1,212 Q1-FY21 Q4-FY21 Q1-FY22 Q1-FY21 Q4-FY21 Q1-FY22 Q1-FY21 Q4-FY21 Q1-FY22 CFS Brazil CFS Wanglong CFS North America Quarterly Operational 591 167 Reve
Slide 12: Country Wise Yearly Performance
Country Wise Yearly Performance CFS India CFS Mexico CFS Europe Operational Revenue 2,735 3,762 5,798 6,000 2,571 3,296 5,481 3,091 2,172 (INR Mn) 2,771 4,050 1,642 2,216 3,376 1,210 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CFS Brazil CFS Wanglong CFS North America
Slide 13: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW
Slide 14: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21 Q1-FY22 Operational Income 5,481 5,798 6,000 1,457 Total Expenses 5,182 5,201 5,382 1,265 EBITDA 299 597 618 192 EBITDA Margin 5.46% 10.30% 10.30% 13.18% Depreciation 91 113 193 64 Finance Cost 203 281 325 96 Other Income 137
Slide 15: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY20 FY21 Particulars (INR Mn) FY20 FY21 EQUITY 3,768 4,646 Non-Current Assets 3,802 4,087 a) Equity Share Capital 121 127 a) Property, Plant and Equipment 686 2,457 b) Other Equity 3,647 4,519 b) Capital Work In Progress 1,742 184 c) Right-Of-Use Assets
Slide 16: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY19 FY20 FY21 Q1-FY22 Operational Income 8,922 10,491 11,871 3,308 Total Expenses 8,235 9,184 10,052 2,852 EBITDA 687 1,307 1,819 456 EBITDA Margin 7.70% 12.46% 15.32% 13.78% Depreciation 290 328 443 134 Finance Cost 367 431 375 101 Othe
Slide 17: Consolidated Balance Sheet
Consolidated Balance Sheet PARTICULARS (INR Mn) FY20 FY21 PARTICULARS (INR Mn) FY20 FY21 EQUITY 4,601 7,131 Non-Current Assets 5,591 6,869 a) Equity Share Capital 121 127 a) Property, Plant and Equipment 2,034 4,818 b) Capital Work In Progress 1,761 237 b) Other Equity 3,910 6,307 c) Right-Of-Use As
Slide 18: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) Debt to EBITDA 28.44 4,000 11,871 2,100 15.32% 18.00% 2,000 10,491 1,800 16.00% 12.46% 1,819 14.00% 0,000 8,922 1,500 7,228 12.00% 8,000 1,200 7.70% 10.00% 5,469 11.40 6,000 900 5.16% 8.00% 1,307 6.00%
Slide 19: Capital Markets
Capital Markets 300.00% 250.00% 200.00% 150.00% 100.00% 50.00% 0.00% Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 -50.00% Sensex Camlin Price Data (30th June, 2021) INR Shareholding Pattern as on 30th June, 2021 Face Value 1.0 Promoters 21.61% Market Price 186.
Slide 20: Disclaimer
Disclaimer Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all e